Table 3.
Baseline characteristics of the patients included in the review
| Study (reference) | Patients | Gender (M/F) | Age (range or ± SD) | CP class (A/B/C) | Cirrhosis etiology (agent %) |
| Monici et al[35] | EBL + EST: 36 | 25/11 | 47.8 (30-68) | 28/8/0 | Alcohol/virus/alcohol+virus/cryptogenic/autoimmune/PSC/PBC 12/13/3/5/2/1 |
| EBL + MC: 34 | 26/8 | 48.5 (22-71) | 29/5/0 | Alcohol/virus/alcohol+ virus/cryptogenic/autoimmune/PSC/PBC 8/11/3/9/1/2 | |
| Luz et al[26] | EBL: 44 | NR | NR | 2/22/20 | Alcohol/virus/secondary biliary cirrhosis/cryptogenic/PBC 43.2/43.2/9.1/2.3/2.3 |
| EST: 39 | NR | NR | 3/21/15 | Alcohol/virus/secondary biliary cirrhosis/cryptogenic/PBC 43.6/38.5/7.7/5.1/5.1 | |
| Santos et al[34] | EBL: 20 | 13/7 | 52 ± 12.6 | 0/4/16 | Alcohol/HCV/alcohol+HCV/other 30/30/15/25 |
| CI: 18 | 14/4 | 51 ± 8.2 | 0/3/15 | Alcohol/HCV/alcohol+HCV/other 39/33/6/22 | |
| Lo et al[31] | EBL+ vasoconstrictors: 60 | 49/11 | 52.5 ± 14.4 | 18/32/10 | Alcohol/HBV/HCV/HBV+HCV/cryptogenic 40/22/30/3/5 |
| EBL+PPIs: 58 | 49/9 | 54.2 ± 9.7 | 15/24/19 | Alcohol/HBV/HCV/HBV+HCV/cryptogenic 38/29/26/3/2/2 | |
| Stanley et al[30] | EBL: 31 | 21/10 | 49.6 ± 12.87 | 11/28/25 | Alcohol/NAFLD/PBC/DICLD 91/5/3/2 |
| Carvedilol: 33 | 22/11 | 51.4 ± 10.8 | |||
| Chen et al[28] | EBL: 48 | 32/16 | 56 ± 10 | 19/29/0 | HBV/HCV/Alcohol/autoimmune/other 59/4/6/8/23 |
| EST: 48 | 31/17 | 54 ± 11 | 20/28/0 | HBV/HCV/alcohol/autoimmune/other 75/0/2/10/13 | |
| Holster et al[32] | EBL+β-blockers: 35 | 23/12 | 54 (30-71) | 13/18/4 | Alcohol/HBV+HCV/alcohol + HBV+HCV/autoimmune liver+biliary disease/other 51/3/8/26/11 |
| TIPS: 37 | 18/19 | 56 (37-75) | 13/19/5 | Alcohol/HBV+HCV/alcohol + HBV+HCV/autoimmune liver+biliary disease/other 35/19/8/24/14 | |
| Mansour et al[27] | EBL: 60 | 34/26 | NR | 8/20/32 | HCV/HBV/HCV+HBV 86.67/6.66/6.66 |
| EBL + EST: 60 | 44/16 | NR | 14/22/24 | HCV/HBV/HCV+HBV 86.67/6.66/6.66 | |
| Lv et al[33] | EBL+propranolol: 25 | 16/8 | 46 (38-56) | 10/14/1 | HBV/HCV/alcohol/AH/HBV+AH/cryptogenic 86.67/13.3/0 |
| TIPS: 24 | 13/12 | 49 (46-62) | 9/13/2 | HBV/HCV/alcohol/AH/HBV+AH/cryptogenic 83/4/4/4/0/4 | |
| Hanif et al[29] | EBL+ propranolol: 30 | 25/5 | 56.30 ± 5.80 | NR | NR |
| Propranolol: 30 | 13/17 | 57.63 ± 5.98 | NR | NR |
CP: Child Pugh; EBL: Endoscopic band ligation; EST: Endoscopic sclerotherapy; PSC: Primary sclerosing cholangitis; PBC: Primary biliary cirrhosis; MC: Microwave coagulation; NR: Not reported; HCV: Hepatitis C virus; HBV: Hepatitis B virus; CI: Cyanoacrylate injection; AH: Autoimmune hepatitis; NAFLD: Non-alcoholic fatty liver disease; PPIs: Proton pump inhibitors; DICLD: Drug-induced chronic liver disease; TIPS: Transjugular intrahepatic portosystemic shunt; NSBBs: Non-selective β-blockers.